In vivo fate of polymeric gene carriers

Biomaterials for Delivery and Targeting of Proteins and Nucleic Acids

Volumn , Issue , 2004, Pages 295-321

  Fischer, Dagmar ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 38949084214     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (117)

1. Ledley, F. D., Pharmaceutical approach to somatic gene therapy. Pharm. Res., 1996; 13: 1595-1614.
2. Mahato, R. I., Takakura, Y., and Hashida, M., Nonviral vectors for in vivo gene delivery: physicochemical and pharmacokinetic considerations. Crit. Rev. Ther. Drug. Carrier Syst., 1997; 14: 133-172.
3. Merdan, T., Kopecek, J., and Kissel, T., Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv. Drug Deliv. Rev., 2002; 54: 715-758.
4. De Smedt, S. C., Demeester, J., and Hennink, W. E., Cationic polymer based gene delivery systems. Pharm. Res., 2000; 17: 113-126.
5. Thomas, M., and Klibanov, A. M., Non-viral gene therapy: polycationmediated DNA delivery. Appl. Microbiol. Biotechnol., 2003; 62: 27-34.
6. Oh, Y. K. et al., Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes. Gene Ther., 2001; 8: 1587-1592.
7. Dash, P. R. et al., Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther., 1999; 6: 643-650.
8. Liu, F., Qi, H., Huang, L., and Liu, D., Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration. Gene Ther, 1997; 4: 517-523.
9. Yockman, J. W., Maheshwari, A., Han, S. O., Kim, S. W., Tumor regression by repeated intratumoral delivery of water soluble lipopolymers/p2CMVmIL-12 complexes. J. Control Release, 2003; 87: 177-186.
10. Kircheis, R. et al., Polyethylenimine/DNA complexes shielded by transferrin target gene expression to tumors after systemic application. Gene Ther., 2001; 8: 28-40.
11. Barratt, G., Colloidal drug carriers: achievements and perspectives. Cell Mol. Life Sci., 2003; 60: 21-37.
12. Oupicky, D. et al., Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol. Ther., 2002; 5: 463-472.
13. Agrawal, S., Temsamani, J., Galbraith, W., Tang, J., Pharmacokinetics of antisense oligonucleotides. Clin. Pharmacokinet., 1995; 28: 7-16.
14. Engelhard, H. H., Antisense oligodeoxynucleotide technology: potential use for the treatment of malignant brain tumors. Cancer Control, 1998; 5: 163-170.
15. Ward, C. M., Read, M. L., Seymour, L. W., Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy. Blood, 2001; 97: 2221-2229.
16. Hughes, M. D. et al., The cellular delivery of antisense oligonucleotides and ribozymes. Drug Discov. Today, 2001; 6: 303-315.
17. Takakura, Y., Nishikawa, M., Yamashita, F., and Hashida, M., Development of gene drug delivery systems based on pharmacokinetic studies. Eur. J. Pharm. Sci, 2001; 13: 71-76.
18. Fischer, D. et al., Administration of NF-kappaB decoy oligonucleotides using polyethylenimine as nonviral vector system. Proceed. Intern. Symp. Control Rel. Bioac. Mater., 2001.
19. Sioud, M., and Leirdal, M., Therapeutic RNA and DNA enzymes. Biochem. Pharmacol., 2000; 60: 1023-1026.
20. Miyao, T. et al., Stability and pharmacokinetic characteristics of oligonucleotides modified at terminal linkages in mice. Antisense Res. Dev., 1995; 5: 115-121.
21. Sawai, K. et al., Disposition of oligonucleotides in isolated perfused rat kidney: involvement of scavenger receptors in their renal uptake. J. Pharmacol, Exp. Ther, 1996; 279: 284-290.
22. Agrawal, S., Zhao, Q., Antisense therapeutics. Curr. Opin. Chem. Biol., 1998; 2: 519-528.
23. Muller, R. H., Colloidal Carriers for Controlled Drug Delivery and Targeting. Wissenchaftliche Verlagsesellschaft, Stuttgart, 1991.
24. Ogris, M. et al., PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther., 1999; 6: 595-605.
25. Kunath, K. et al., The structure of PEG-modified poly(ethylene imines) influences biodistribution and pharmacokinetics of their complexes with NF-kappaB decoy in mice. Pharm. Res., 2002; 19: 810-817.
26. Kircheis, R. et al., Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. J. Gene Med., 1999; 1: 111-120.
27. Kircheis, R., and Wagner, E., Polycation-based DNA complexes for tumor-targeted gene delivery in vivo. Gene. Ther. Regul., 2000; 1: 95.
28. Trubetskoy, V. S. et al., Recharging cationic DNA complexes with highly charged polyanions for in vitro and in vivo gene delivery. Gene Ther., 2003; 10: 261-271.
29. Verbaan, F. J. et al., The fate of poly(2-dimethyl amino ethyl)methacrylate-based polyplexes after intravenous administration. Int. J. Pharm., 2001; 214: 99-101.
30. Oupicky, D. et al., Effect of albumin and polyanion on the structure of DNA complexes with polycation containing hydrophilic nonionic block. Bioconjug. Chem., 1999; 10: 764-772.
31. Tang, M. X., Szoka, F. C., The influence of polymer structure on the interactions of cationic polymers with DNA and morphology of the resulting complexes. Gene Ther., 1997; 4: 823-832.
32. Takakura, Y., and Hashida, M., Pharmacokinetics of macromolecules and synthetic gene delivery systems. In: Kabanov, A. V., Felgner, P. L., and Seymour, L. W. (eds), From Laboratory to Clinical Trials. Wileys, Chichester, 1998, Chapter 15.
33. Taylor, A. E., and Granger, D. N., Equivalent pore modeling: vesicles and channels. Fed. Proc., 1983; 42: 2440-2445.
34. Maeda, H., and Matsumura, Y., Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst., 1989; 6: 193-210.
35. Seymour, L. W., Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Carrier Syst., 1992; 9: 135-187.
36. Juliano, R. L., Factors affecting the clearance kinetics and tissue distribution of liposomes, microspheres and emulsions. Adv. Drug Deliv. Rev., 1988; 2: 31.
37. Plank, C., Mechtler, K., Szoka, F. C., Jr., and Wagner, E., Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum. Gene Ther., 1996; 7: 1437-1446.
38. Siegal, J. et al., Interactions of C-reactive protein with the complement system, II: C-reactive protein-based mediated consumption of complement by poly-L-lysine polymers and other polycations. J. Exp. Med., 1975; 142: 709.
39. Mullen, P. M. et al., Strength of conjugate binding to plasmid DNA affects degradation rate and expression level in vivo. Biochim. Biophys. Acta, 2000; 1523: 103-110.
40. Zou, S. M., Erbacher, P., Remy, J. S., and Behr, J. P., Systemic linear polyethylenimine (L-PEI)-mediated gene delivery in the mouse. J. Gene Med., 2000; 2: 128-134.
41. Goula, D. et al., Rapid crossing of the pulmonary endothelial barrier by polyethylenimine/DNA complexes. Gene Ther., 2000; 7: 499-504.
42. Aziz, S. M., Olson, J. W., Gillespie, M. N., Multiple polyamine transport pathways in cultured pulmonary artery smooth muscle cells: regulation by hypoxia. Am. J. Respir. Cell Mol. Biol., 1994; 10: 160-166.
43. Ma, X. et al., Focal arterial transgene expression after local gene delivery. Can. J. Cardiol, 2001; 17: 873-883.
44. Armeanu, S. et al., Optimization of nonviral gene transfer of vascular smooth muscle cells in vitro and in vivo. Mol. Ther., 2000; 1: 366-375.
45. Baranov, A. et al., Local and distant transfection of mdx muscle fibers with dystrophin and LacZ genes delivered in vivo by synthetic microspheres. Gene Ther, 1999; 6: 1406-1414.
46. Gautam, A. et al., Transgene expression in mouse airway epithelium by aerosol gene therapy with PEI-DNA complexes. Mol. Ther., 2001; 3: 551-556.
47. Jia, S. F. et al., Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin. Cancer Res., 2003; 9: 3462-3468.
48. Gautam, A., Waldrep, J. C., and Densmore, C. L., Aerosol gene therapy. Mol. Biotechnol., 2003; 23: 51-60.
49. Bragonzi, A., and Conese, M., Non-viral approach toward gene therapy of cystic fibrosis lung disease. Curr. Gene Ther., 2002; 2: 295-305.
50. Aigner, A. et al., Delivery of unmodified bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-regulates gene expression. Gene Ther., 2002; 9: 1700-1707.
51. Aoki, K. et al., Polyethylenimine-mediated gene transfer into pancreatic tumor dissemination in the murine peritoneal cavity. Gene Ther., 2001; 8: 508-514.
52. Coll, J. L. et al., In vivo delivery to tumors of DNA complexed with linear polyethylenimine. Hum. Gene Ther., 1999; 10: 1659-1666.
53. Goula, D. et al., Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse central nervous system. Gene Ther., 1998; 5: 712-717.
54. Lemkine, G. F. et al., Optimisation of polyethylenimine-based gene delivery to mouse brain. J. Drug Target., 1999; 7: 305-312.
55. Wang, S. et al., Transgene expression in the brain stem effected by intramuscular injection of polyethylenimine/DNA complexes. Mol. Ther., 2001; 3: 658-664.
56. Abdallah, B. et al., A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum. Gene Ther., 1996; 7: 19471954.
57. Ouatas, T., Le Mevel, S., Demeneix, B. A., and de Luze, A., T3-dependent physiological regulation of transcription in the Xenopus tadpole brain studied by polyethylenimine based in vivo gene transfer. Int. J. Dev. Biol., 1998; 42: 1159-1164.
58. Demeneix, B. A., Ghorbel, M., and Goula, D., Optimizing polyethylenimine-based gene transfer into mammalian brain for analysis of promoter regulation and protein function. Methods Mol. Biol., 2000; 133: 21-35.
59. Shi, L. et al., Repeated intrathecal administration of plasmid DNA complexed with polyethylene glycol-grafted polyethylenimine led to prolonged transgene expression in the spinal cord. Gene Ther., 2003; 10: 1179-1188.
60. Boletta, A. et al., Nonviral gene delivery to the rat kidney with polyethylenimine. Hum. Gene Ther., 1997; 8: 1243-1251.
61. Sawa, Y. et al., Efficient transfer of oligonucleotides and plasmid DNA into the whole heart through the coronary artery. Gene Ther., 1998; 5: 1472-1480.
62. Brus, C., Santi, P., Colombo, P., and Kissel, T., Distribution and quantification of polyethylenimine oligodeoxynucleotide complexes in human skin after iontophoretic delivery using confocal scanning laser microscopy. J. Control Release, 2002; 84: 171-181.
63. Meuli, M. et al., Efficient gene expression in skin wound sites following local plasmid injection. J. Invest. Dermatol., 2001; 116: 131-135.
64. Groneberg, D. A. et al., Fundamentals of pulmonary drug delivery. Respir. Med., 2003; 97: 382-387.
65. Niven, R. W., Delivery of biotherapeutics by inhalation aerosol. Crit. Rev. Ther. Drug Carrier Syst., 1995; 12: 151-231.
66. Davies, J. C. et al., Pulmonary gene therapy. In: Rolland, A., and Sullivan, S. M. (eds), Pharmaceutical Gene Delivery Systems. Marcel Dekker, Inc., New York, 2003, Chapter 14.
67. Rudolph, C. et al., In vivo gene delivery to the lung using polyethylenimine and fractured polyamidoamine dendrimers. J. Gene Med., 2000; 2: 269-278.
68. Uyechi, L. S., Gagne, L., Thurston, G., Szoka, F. C., Jr., Mechanism of lipoplex gene delivery in mouse lung: binding and internalization of fluorescent lipid and DNA components. Gene. Ther., 2001; 8: 828-836.
69. Griesenbach, U. et al., Comparison between intratracheal and intravenous administration of liposome-DNA complexes for cystic fibrosis lung gene therapy. Gene Ther., 1998; 5: 181-188.
70. Stribling, R. et al., Aerosol gene delivery in vivo. Proc. Natl. Acad. Sci. USA, 1992; 89: 11277-11281.
71. Guillaume, C. et al., Aerosolization of cationic lipid-DNA complexes: lipoplex characterization and optimization of aerosol delivery conditions. Biochem. Biophys. Res. Commun., 2001; 286: 464-471.
72. Densmore, C. L. et al., Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes. Cancer Gene Ther., 2001; 8: 619-627.
73. Rosenecker, J. et al., Interaction of bronchoalveolar lavage fluid with polyplexes and lipoplexes: analysing the role of proteins and glycoproteins. J. Gene Med., 2003; 5: 49-60.
74. Koping-Hoggard, M. et al., Chitosan as a nonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther., 2001; 8: 1108-1121.
75. Gautam, A., Densmore, C. L., Xu, B., and Waldrep, J. C., Enhanced gene expression in mouse lung after PEI-DNA aerosol delivery. Mol. Ther., 2000; 2: 63-70.
76. Evora, C. et al., Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidyl-choline. J. Control Release, 1998; 51: 143-152.
77. Lacasse, F. X. et al., Influence of surface properties at biodegradable microsphere surfaces: effects on plasma protein adsorption and phagocytosis. Pharm. Res., 1998; 15: 312-317.
78. Goldstein, G. W., and Betz, A. L., The blood-brain barrier. Sci. Am., 1986; 255: 74-83.
79. Bickel, U., Yoshikawa, T., and Pardridge, W. M., Delivery of peptides and proteins through the blood-brain barrier. Adv. Drug Deliv. Rev., 2001; 46: 247-279.
80. Zhang, Y., Boado, R. J., Pardridge, W. M., Marked enhancement in gene expression by targeting the human insulin receptor. J. Gene Med., 2003; 5: 157-163.
81. Zhang, Y. et al., Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum. Gene Ther., 2003; 14: 1-12.
82. Martres, M. P. et al., Up- and down-expression of the dopamine transporter by plasmid DNA transfer in the rat brain. Eur. J. Neurosci., 1998; 10: 3607-3616.
83. Dass, C. R., Vehicles for oligonucleotide delivery to tumours. J. Pharm. Pharmacol., 2002; 54: 3-27.
84. Thurston, G. et al., Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J. Clin. Invest., 1998; 101: 1401-1413.
85. Iwai, M. et al., Polyethylenimine-mediated suicide gene transfer induces a therapeutic effect for hepatocellular carcinoma in vivo by using an Epstein-Barr virus-based plasmid vector. Biochem. Biophys. Res. Commun., 2002; 291:48-54.
86. Dolivet, G. et al., In vivo growth inhibitory effect of iterative wild-type p53 gene transfer in human head and neck carcinoma xenografts using glucosylated polyethylenimine nonviral vector. Cancer Gene Ther., 2002; 9: 708-714.
87. Kwoh, D. Y. et al., Stabilization of poly-L-lysine/DNA polyplexes for in vivo gene delivery to the liver. Biochim. Biophys. Acta, 1999; 1444: 171-190.
88. Nguyen, H. K. et al., Evaluation of polyether-polyethyleneimine graft copolymers as gene transfer agents. Gene Ther., 2000; 7: 126-138.
89. Toncheva, V. et al., Novel vectors for gene delivery formed by self-assembly of DNA with poly(L-lysine) grafted with hydrophilic polymers. Biochim. Biophys. Acta, 1998; 1380: 354-368.
90. Gebhart, C. L. et al., Design and formulation of polyplexes based on pluronic-polyethyleneimine conjugates for gene transfer. Bioconjug. Chem., 2002; 13: 937-944.
91. Ochietti, B. et al., Inducing neutrophil recruitment in the liver of ICAM-1-deficient mice using polyethyleneimine grafted with Pluronic P123 as an organ-specific carrier for transgenic ICAM-1. Gene Ther., 2002; 9: 939-945.
92. Ochietti, B. et al., Altered organ accumulation of oligonucleotides using polyethyleneimine grafted with poly(ethylene oxide) or pluronic as carriers. J. Drug Target., 2002; 10: 113-121.
93. Oupicky, D. et al., Steric stabilization of poly-L-Lysine/DNA complexes by the covalent attachment of semitelechelic poly[N-(2-hydroxypropyl)methacryla-mide]. Bioconjug. Chem., 2000; 11: 492-501.
94. Seymour, L. W., Kataoka, K., and Kabanov, A. V., Cationic block copolymers as self-assembling vectors for gene delivery. In: Kabanov, A. V., Felgner, P. L., and Seymour, L. W. (eds), From Laboratory to Clinical Trial. Wiley: Chichester, 1998, Chapter 11.
95. Mori, A., Klibanov, A. L., Torchilin, V. P., Huang, L., Influence of the steric barrier activity of amphipathic poly(ethyleneglycol) and ganglioside GM1 on the circulation time of liposomes and on the target binding of immunoliposomes in vivo. FEBS Lett., 1991; 284: 263-266.
96. Merdan, T., Polyethylenimine and its derivatives: Investigation of in vivo fate, subcellular trafficking and development of nover vector systems. Department of Pharmaceutical Sciences. Phillips University, Marburg, Germany, 2003. http://archiv.ub.uni-marburg.de/diss/z2003/2065/pdf/Chap-ter2006.pdf
97. Oupicky, D., Carlisle, R. C., and Seymour, L. W., Triggered intracellular activation of disulfide crosslinked polyelectrolyte gene delivery complexes with extended systemic circulation in vivo. Gene Ther., 2001; 8: 713-724.
98. Takakura, Y., and Hashida, M., Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res., 1996; 13: 820-831.
99. Matsumura, Y., and Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 1986; 46: 6387-6392.
100. Chollet, P., Favrot, M. C., Hurbin, A., and Coll, J. L., Side-effects of a systemic injection of linear polyethylenimine-DNA complexes. J. Gene Med., 2002; 4: 84-91.
101. Kichler, A., Behr, J. P., and Erbacher, P., Polyethylenimines: A family of protein polymers for nucleic acid delivery. In: Huang, L., Hung, M. C., and Wagner, E. (eds), Nonviral Vectors for Gene Therapy. Academic Press, San Diego, 1999, Chapter 9.
102. Kunath, K., von Harpe, A., Fischer, D., and Kissel, T., Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency. J. Control Release, 2003; 88: 159-172.
103. Fischer, D. et al., Effect of poly (ethylene imine) molecular weight and PEGylation on organ distribution and pharmacokinetics of polyplexes with oligodeoxynucleotides in mice. Drug Metab. Dispos., 2004; 32: 983-992.
104. Wagner, E. et al., Transferrin-polycation conjugates as carriers for DNA uptake into cells. Proc. Natl. Acad. Sci. USA, 1990; 87: 3410-3414.
105. Wu, G. Y., and Wu, C. H., Evidence for targeted gene delivery to Hep G2 hepatoma cells in vitro. Biochemistry, 1988; 27: 887-892.
106. Chen, J., Stickles, R. J., and Daichendt, K. A., Galactosylated histone-mediated gene transfer and expression. Hum. Gene Ther., 1994; 5: 429-435.
107. Diebold, S. S. et al., Mannose receptor-mediated gene delivery into antigen presenting dendritic cells. Somat. Cell Mol. Genet., 2002; 27: 65-74.
108. Kunath, K. et al., Integrin targeting using RGD-PEI conjugates for in vitro gene transfer. J. Gene Med., 2003; 5: 588-599.
109. Benns, J. M. et al., Folate-PEG-folate-graft-polyethylenimine-based gene delivery. J. Drug Target, 2001; 9: 123-139.
110. Mislick, K. A. et al., Transfection of folate-polylysine DNA complexes: evidence for lysosomal delivery. Bioconjug. Chem., 1995; 6: 512-515.
111. Oupicky, D., Parker, A. L., Seymour, L. W. Laterally stabilized complexes of DNA with linear reducible polycations: strategy for triggered intracellular activation of DNA delivery vectors. J. Am. Chem. Soc., 2002; 124: 8-9.
112. Ogris, M. et al., Tumor-targeted gene therapy: strategies for the preparation of ligand-polyethylene glycol-polyethylenimine/DNA complexes. J. Control Rel., 2003; 91, 173-181.
113. O’Neill, M. M. et al., Receptor-mediated gene delivery to human peripheral blood mononuclear cells using anti-CD3 antibody coupled to polyethylenimine. Gene Ther., 2001; 8: 362-368.
114. Ferkol, T., Kaetzel, C. S., and Davis, P. B., Gene transfer into respiratory epithelial cells by targeting the polymeric immunoglobulin receptor. J. Clin. Invest, 1993; 92: 2394-2400.
115. Chen, J. et al., A novel gene delivery system using EGF receptor-mediated endocytosis. FEBS Lett., 1994; 338: 167-169.
116. Trubetskoy, V. S. et al., Use of N-terminal modified poly(L-lysine)-antibody conjugate as a carrier for targeted gene delivery in mouse lung endothelial cells. Bioconjug. Chem.,1992; 3: 323-327.
117. Li, S. et al., Targeted gene delivery to pulmonary endothelium by anti-PECAM antibody. Am. J. Physiol. Lung Cell Mol. Physiol., 2000; 278: L504-511.